CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 6, 2018-- Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of its initial public offering of 26,275,993 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts and commissions. Moderna’s common stock is expected to begin trading on The Nasdaq Global Select Market on December 7, 2018 under the ticker symbol “MRNA.” All of the common stock is being offered by Moderna. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Moderna, are expected to be $604.3 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 11, 2018, subject to satisfaction of customary closing conditions. Moderna has granted the underwriters a 30-day option to purchase up to an additional 3,941,398 shares of Moderna’s common stock at the initial public offering price, less underwriting discounts and commissions.
Morgan Stanley, Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering. BofA Merrill Lynch, Barclays Capital Inc. and Piper Jaffray & Co. are acting as book-running managers for the offering. Oddo BHF SCA, Oppenheimer & Co. Inc., Needham & Company, LLC and Chardan are acting as co-managers for the offering.
Registration statements relating to the shares being sold in this offering have been filed with the Securities and Exchange Commission and were declared effective on December 6, 2018. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or email: firstname.lastname@example.org; or from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866- 803-9204, or email: email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.
Moderna pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines to direct the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181206006060/en/
Source: Moderna, Inc.
Head of Corporate Communications
Chief Financial Officer